“`html
Gilead Sciences (NASDAQ: GILD) has faced a setback with an FDA clinical hold on its HIV treatment trials, GS-1720 and GS-4182, due to declines in CD4+ T-cell counts. Despite this, the company has seen its stock rise 18% year-to-date, significantly outperforming the S&P 500’s 2% gain. Gilead is currently collaborating with regulators to address the issue while focusing on profitability.
As of June 17, 2025, Gilead’s stock is valued at approximately $110 per share, with 16 programs in late-stage clinical development. The company’s annual revenue grew 4.7% over the last year, increasing from $27 billion to $29 billion, although quarterly revenue dipped 0.3% year-over-year to $6.7 billion. Gilead also has a debt-to-equity ratio of 18.1% and maintains a strong operating margin of 37.4%.
Overall, Gilead has shown strong profitability, with superior margins compared to many peers, and maintains a healthy financial position. Investors are assessing the potential for further upside, backed by a solid balance sheet and resilient performance during market downturns.
“`
